SCGB1D4 Inhibitors
SCGB1D4 inhibitors represent a class of molecules that interact with the secretoglobin family 1D member 4 (SCGB1D4) protein, which belongs to the larger secretoglobin superfamily. Secretoglobins are small, secreted proteins that are known to play diverse roles in various biological systems, particularly in processes related to cellular signaling, immune modulation, and response to environmental stimuli. SCGB1D4 is a relatively understudied member of this family, and its specific molecular functions are still under investigation. Inhibitors targeting SCGB1D4 generally operate by binding to this protein or its interacting partners, altering its conformational state or hindering its interactions with other cellular components, thereby modulating its biological activity. The inhibition of SCGB1D4 may lead to downstream effects on cellular communication pathways, including the regulation of gene expression and cellular behavior, depending on the context in which this protein is expressed.
From a chemical perspective, SCGB1D4 inhibitors can exhibit a wide variety of structural motifs, which can vary based on the inhibitor's mechanism of action and the binding sites involved. These inhibitors might be small organic molecules, peptides, or even larger biomolecules that can specifically target and bind to SCGB1D4. Structure-activity relationship (SAR) studies can be pivotal in understanding how modifications in the chemical structure of these inhibitors affect their binding affinity, selectivity, and potency. The design of such inhibitors typically requires detailed biochemical knowledge of SCGB1D4's structure and function, as well as advanced molecular modeling techniques to predict how inhibitors interact with the protein at the atomic level. Such efforts contribute to understanding the role of SCGB1D4 in complex biological systems, shedding light on the intricate molecular networks that govern cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $168.00 $218.00 $404.00 $629.00 $4900.00 | 19 | |
Marimastat is a broad-spectrum matrix metalloprotease (MMP) inhibitor. SCGB1D4 has been associated with extracellular matrix remodeling. By inhibiting MMPs, Marimastat can prevent the remodeling of the extracellular matrix, which is essential for the function of SCGB1D4 in cell migration and tissue repair. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor. SCGB1D4's function can be linked to proteolytic processing. E-64 can inhibit this process by covalently binding to the active site of cysteine proteases, thereby inhibiting the protease activity that SCGB1D4 could be involved in. | ||||||
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $199.00 $632.00 | 8 | |
Phosphoramidon is a metalloprotease inhibitor. SCGB1D4 could be involved in pathways facilitated by metalloprotease activity. The inhibition of these proteases by Phosphoramidon could lead to an indirect inhibition of SCGB1D4's functional role in these pathways. | ||||||
Aprotinin | 9087-70-1 | sc-3595 sc-3595A sc-3595B | 10 mg 100 mg 1 g | $112.00 $408.00 $3000.00 | 51 | |
Aprotinin is a serine protease inhibitor. By inhibiting serine proteases, Aprotinin can potentially inhibit proteolytic processes that SCGB1D4 may be involved with, thus indirectly leading to the functional inhibition of SCGB1D4. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is an inhibitor of serine and cysteine proteases. If SCGB1D4's function is related to these proteases, Leupeptin's inhibitory effect on them could result in a decrease in SCGB1D4's functional activity. | ||||||
Chymostatin | 9076-44-2 | sc-202541 sc-202541A sc-202541B sc-202541C sc-202541D | 5 mg 10 mg 25 mg 50 mg 100 mg | $156.00 $260.00 $640.00 $1186.00 $2270.00 | 3 | |
Chymostatin is a chymotrypsin inhibitor. Chymotrypsin-like activity could be essential for SCGB1D4's function; thus, the use of Chymostatin can inhibit this activity, leading to a functional inhibition of SCGB1D4. | ||||||
Bestatin | 58970-76-6 | sc-202975 | 10 mg | $131.00 | 19 | |
Bestatin is an aminopeptidase inhibitor. SCGB1D4 could be involved in pathways where aminopeptidase activity is crucial. Bestatin can inhibit this activity, potentially leading to the indirect functional inhibition of SCGB1D4. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone is a selective PPAR-gamma agonist, but it can also inhibit CYP2C8 enzymes. If SCGB1D4 were involved in a pathway with CYP2C8 activity, Pioglitazone could indirectly inhibit the function of SCGB1D4 by inhibiting CYP2C8 enzymes. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 is a PPAR-gamma antagonist. While its primary action is antagonism, it can also inhibit related pathways. If SCGB1D4's activity were related to PPAR-gamma-regulated pathways, GW9662 could indirectly inhibit SCGB1D4 by blocking these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor. SCGB1D4 could be involved in MEK/ERK pathway. The inhibition of MEK by PD98059 can lead to the downstream inhibition of the pathway, potentially inhibiting the function of SCGB1D4. | ||||||